The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

As demand soared for weight-loss drugs, price signals worked.

Robert F. Kennedy Jr. has given his first network television interview since becoming health secretary to Dr. Jon LaPook.

The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

A retrospective study found that women who took a GLP-1 drug for obesity were more likely to be diagnosed with acne vulgaris ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...